Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Assets Average (2016 - 2025)

Historic Assets Average for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $90.2 million.

  • Lineage Cell Therapeutics' Assets Average fell 950.77% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.2 million, marking a year-over-year decrease of 950.77%. This contributed to the annual value of $107.1 million for FY2024, which is 464.92% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Assets Average stood at $90.2 million, which was down 950.77% from $101.3 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Assets Average registered a high of $159.5 million during Q1 2022, and its lowest value of $90.2 million during Q3 2025.
  • Moreover, its 5-year median value for Assets Average was $112.5 million (2025), whereas its average is $118.9 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Assets Average surged by 4488.18% in 2021 and then plummeted by 2576.15% in 2023.
  • Lineage Cell Therapeutics' Assets Average (Quarter) stood at $152.9 million in 2021, then fell by 16.66% to $127.4 million in 2022, then fell by 18.7% to $103.6 million in 2023, then grew by 1.27% to $104.9 million in 2024, then decreased by 14.0% to $90.2 million in 2025.
  • Its Assets Average was $90.2 million in Q3 2025, compared to $101.3 million in Q2 2025 and $112.5 million in Q1 2025.